We chose to target PD-L1 over PD-1 because by binding PD-L1 on cancer cells or APCs and TIGIT/LAG-3 on T cells, these antibodies can bridge APCs and cancer cells with T cells, improving the quality of immune synapses, and resulting in stronger T cell activation and tumor cell killing. This evidence concerns the gene CD274 and neoplasm.